See a doctor who has experience with it. You’ll find dermatologists who have experience with cutaneous T-cell lymphoma at Find a Dermatologist. Click on "Filters". Select "Any condition" and choose ...

IL-6 contributes to the aggressiveness and systemic symptoms of diffuse large B-cell lymphoma and Hodgkin's lymphoma. The microenvironment of Hodgkin's lymphoma is affected by IL-5 which recruits ...

Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy treatment regimen ...

Innate Pharma has gained breakthrough therapy designation for lacutamab to treat adults with relapsed or refractory Sézary ...

Feb. 13, 2025 -- The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL). LBCL is a fast-growing cancer of B ...

Panel B shows the patient at the initial T-cell lymphoma (TCL) presentation before biopsy. Panel C shows anticamelid staining (which detects the llama-derived CAR) of the lymph-node biopsy sample ...

Lymphoma is a type of cancer that begins in immune system cells, called lymphocytes. It generally presents as a solid tumor of lymphoid cells and can develop in the lymph nodes, spleen, bone ...

B-cell lymphoma is a type of blood cancer that affects the B lymphocytes of the immune system. They usually arise in the lymph nodes or in other lymphoid tissue, such as the spleen, bone marrow ...

Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma: New York Friday, February 14, 2025, 11:00 Hrs [IST] Pfizer ...

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® (brentuximab vedotin) in combination with ...

Matthew S. McKinney, MD, reflects on his first experience of treating a patient with diffuse large B-cell lymphoma (DLBCL) as a new attending at Duke University. The patient, a woman with multiple ...

A systematic risk assessment of more prevalent lymphoma entities, such as B cell and non-intestinal lymphomas, in coeliac disease has not been performed. Aims: In light of the increasing number of ...